Form FDA356H Application to Market a New or Abbreviated New Drug or Biologic for Human Use

Form FDA356H Application to Market a New or Abbreviated New Drug or Biologic for Human Use

What Is Form FDA356H?

This is a legal form that was released by the U.S. Department of Health and Human Services - U.S. Food and Drug Administration on August 1, 2018 and used country-wide. Check the official instructions before completing and submitting the form.

FAQ

Q: What is Form FDA356H?
A: Form FDA356H is an application used to request approval for marketing a new or abbreviated new drug or biologic for human use.

Q: Who uses Form FDA356H?
A: Pharmaceutical companies and manufacturers use Form FDA356H to seek approval from the FDA to market new drugs or biologics for human use.

Q: What does the form require?
A: The form requires detailed information about the drug or biologic, including its composition, manufacturing process, clinical data, proposed labeling, and more.

Q: What is the purpose of Form FDA356H?
A: The purpose of Form FDA356H is to provide the FDA with the necessary information to evaluate the safety and effectiveness of a new drug or biologic before granting approval.

Q: What is the difference between a new drug and an abbreviated new drug?
A: A new drug refers to a drug that contains an active ingredient that has never been approved by the FDA, while an abbreviated new drug is a generic version of an already approved drug.

Q: What happens after submitting Form FDA356H?
A: After submitting the form, the FDA reviews the application, conducts inspections if necessary, and evaluates the data provided to make a decision on approval.

Q: Is there a fee for submitting Form FDA356H?
A: Yes, there are fees associated with submitting Form FDA356H. The specific fee amount depends on the type of application being submitted.

Q: How long does it take for the FDA to review Form FDA356H?
A: The FDA aims to review standard applications within ten months from the date of submission, but the actual review time may vary depending on the complexity of the application.

Q: What happens if Form FDA356H is approved?
A: If the application is approved, the pharmaceutical company or manufacturer can proceed with marketing the new drug or biologic for human use under the conditions specified by the FDA.

ADVERTISEMENT

Form Details:

  • Released on August 1, 2018;
  • The latest available edition released by the U.S. Department of Health and Human Services - U.S. Food and Drug Administration;
  • Easy to use and ready to print;
  • Yours to fill out and keep for your records;
  • Compatible with most PDF-viewing applications;
  • Fill out the form in our online filing application.

Download a fillable version of Form FDA356H by clicking the link below or browse more documents and templates provided by the U.S. Department of Health and Human Services - U.S. Food and Drug Administration.

Download Form FDA356H Application to Market a New or Abbreviated New Drug or Biologic for Human Use

4.8 of 5 (72 votes)
  • Form FDA356H Application to Market a New or Abbreviated New Drug or Biologic for Human Use

    1

  • Form FDA356H Application to Market a New or Abbreviated New Drug or Biologic for Human Use, Page 2

    2

  • Form FDA356H Application to Market a New or Abbreviated New Drug or Biologic for Human Use, Page 3

    3

  • Form FDA356H Application to Market a New or Abbreviated New Drug or Biologic for Human Use, Page 1
  • Form FDA356H Application to Market a New or Abbreviated New Drug or Biologic for Human Use, Page 2
  • Form FDA356H Application to Market a New or Abbreviated New Drug or Biologic for Human Use, Page 3
Prev 1 2 3 Next
ADVERTISEMENT